WO2003035696A3 - Humanized antibodies against icam-1, their production and uses - Google Patents
Humanized antibodies against icam-1, their production and uses Download PDFInfo
- Publication number
- WO2003035696A3 WO2003035696A3 PCT/US2002/023002 US0223002W WO03035696A3 WO 2003035696 A3 WO2003035696 A3 WO 2003035696A3 US 0223002 W US0223002 W US 0223002W WO 03035696 A3 WO03035696 A3 WO 03035696A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- humanized antibodies
- production
- antibodies against
- against icam
- antibodies
- Prior art date
Links
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 title abstract 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 title abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT02798403T ATE490276T1 (en) | 2001-07-19 | 2002-07-19 | HUMANIZED ANTIBODIES AGAINST ICAM-1, THEIR PRODUCTION AND USES |
JP2003538209A JP4516312B2 (en) | 2001-07-19 | 2002-07-19 | Humanized antibodies against ICAM-1, their production and use |
EP02798403A EP1414861B1 (en) | 2001-07-19 | 2002-07-19 | Humanized antibodies against icam-1, their production and uses |
DE60238485T DE60238485D1 (en) | 2001-07-19 | 2002-07-19 | HUMANIZED ANTIBODIES TO ICAM-1, THEIR PREPARATION AND USES |
DK02798403.8T DK1414861T3 (en) | 2001-07-19 | 2002-07-19 | Humanized antibodies to ICAM-1, preparation and use thereof |
CA2454361A CA2454361C (en) | 2001-07-19 | 2002-07-19 | Humanized antibodies |
AU2002363027A AU2002363027C1 (en) | 2001-07-19 | 2002-07-19 | Humanized antibodies against ICAM-1, their production and uses |
AU2008258214A AU2008258214B2 (en) | 2001-07-19 | 2008-12-18 | Humanized antibodies against ICAM-1, their production and uses |
AU2012203365A AU2012203365A1 (en) | 2001-07-19 | 2012-06-07 | Humanized antibodies against ICAM-1, their production and uses |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/910,483 | 2001-07-19 | ||
US09/910,483 US20030035798A1 (en) | 2000-08-16 | 2001-07-19 | Humanized antibodies |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003035696A2 WO2003035696A2 (en) | 2003-05-01 |
WO2003035696A3 true WO2003035696A3 (en) | 2003-11-27 |
Family
ID=25428849
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/023002 WO2003035696A2 (en) | 2001-07-19 | 2002-07-19 | Humanized antibodies against icam-1, their production and uses |
Country Status (10)
Country | Link |
---|---|
US (4) | US20030035798A1 (en) |
EP (2) | EP1414861B1 (en) |
JP (3) | JP4516312B2 (en) |
AT (1) | ATE490276T1 (en) |
AU (3) | AU2002363027C1 (en) |
CA (2) | CA2454361C (en) |
DE (1) | DE60238485D1 (en) |
DK (1) | DK1414861T3 (en) |
ES (1) | ES2356896T3 (en) |
WO (1) | WO2003035696A2 (en) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1039931T3 (en) * | 1997-12-01 | 2005-08-08 | Fang Fang | Multivalent recombinant antibodies to treat HRV infections |
US20030035798A1 (en) * | 2000-08-16 | 2003-02-20 | Fang Fang | Humanized antibodies |
JP2005522192A (en) | 2001-07-19 | 2005-07-28 | パーラン セラピューティクス, インコーポレイテッド | Multimeric proteins and methods of making and using multimeric proteins |
WO2005086568A2 (en) * | 2004-01-26 | 2005-09-22 | Morphosys Ag | Anti-icam-1 human antibodies and uses thereof |
AU2005285152A1 (en) * | 2004-09-10 | 2006-03-23 | Wyeth | Humanized anti-5T4 antibodies and anti-5T4 antibody / calicheamicin conjugates |
GB2430030B (en) * | 2005-09-07 | 2009-04-01 | Ethicon Inc | Diagnostic markers of wound infection III |
GB0525214D0 (en) | 2005-12-12 | 2006-01-18 | Bioinvent Int Ab | Biological materials and uses thereof |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
WO2010112193A1 (en) * | 2009-04-02 | 2010-10-07 | Roche Glycart Ag | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
PL2417156T3 (en) * | 2009-04-07 | 2015-07-31 | Roche Glycart Ag | Trivalent, bispecific antibodies |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
US9090690B2 (en) | 2009-06-18 | 2015-07-28 | Pfizer Inc. | Anti Notch-1 antibodies |
CN102712696A (en) | 2009-09-16 | 2012-10-03 | 弗·哈夫曼-拉罗切有限公司 | Coiled coil and/or tether containing protein complexes and uses thereof |
AR080793A1 (en) | 2010-03-26 | 2012-05-09 | Roche Glycart Ag | BISPECIFIC ANTIBODIES |
GB2482535A (en) * | 2010-08-05 | 2012-02-08 | Hera Pharmaceuticals Inc | Expression of antibody or a fragment thereof in lactobacillus |
GB2482536B (en) | 2010-08-05 | 2013-07-24 | Hera Pharmaceuticals Inc | Expression of antibody or a fragment thereof in lactobacillus |
WO2012022734A2 (en) | 2010-08-16 | 2012-02-23 | Medimmune Limited | Anti-icam-1 antibodies and methods of use |
RU2013110875A (en) | 2010-08-24 | 2014-09-27 | Ф.Хоффманн-Ля Рош Аг | SPECIFIC ANTIBODIES CONTAINING DISSULPHIDE-STABILIZED Fv Fragment |
CA2821130C (en) | 2010-12-15 | 2017-11-07 | Wyeth Llc | Anti-notch1 antibodies |
JP5766296B2 (en) | 2010-12-23 | 2015-08-19 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Polypeptide-polynucleotide complexes and their use in targeted delivery of effector components |
EP2681239B8 (en) | 2011-02-28 | 2015-09-09 | F. Hoffmann-La Roche AG | Antigen binding proteins |
BR112013020338A2 (en) | 2011-02-28 | 2016-10-18 | Hoffmann La Roche | monovalent antigen binding protein, pharmaceutical composition, use of monovalent antigen binding protein, method for treating a patient in need of therapy, method for preparing a monovalent antigen binding protein, nucleic acid, vector and cell hostess |
BR112014019579A2 (en) | 2012-02-10 | 2019-10-15 | Genentech, Inc | SINGLE CHAIN ANTIBODY, POLYNUCLEOTIDE, VECTOR, HOST CELL, METHOD OF PRODUCTION OF A SINGLE CHAIN ANTIBODY, HETEROMULTYMER AND METHOD OF PRODUCTION |
BR112014032193A2 (en) | 2012-06-27 | 2017-06-27 | Hoffmann La Roche | bispecific antibody production and combination determination methods, bispecific antibody, formulation and use of bispecific antibody |
WO2014001325A1 (en) | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof |
CA2922912A1 (en) | 2013-10-11 | 2015-04-16 | F. Hoffmann-La Roche Ag | Multispecific domain exchanged common variable light chain antibodies |
EP3144388B1 (en) * | 2014-05-13 | 2020-07-01 | Chugai Seiyaku Kabushiki Kaisha | T cell-redirecting antigen-binding molecule for cells having immunosuppression function |
WO2016087416A1 (en) | 2014-12-03 | 2016-06-09 | F. Hoffmann-La Roche Ag | Multispecific antibodies |
WO2017086367A1 (en) | 2015-11-18 | 2017-05-26 | 中外製薬株式会社 | Combination therapy using t cell redirection antigen binding molecule against cell having immunosuppressing function |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991016927A1 (en) * | 1990-04-27 | 1991-11-14 | Celltech Limited | Humanized cdr-grafted anti-icam-1 antibodies, methods of preparation and usage thereof |
Family Cites Families (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
FR2562421B1 (en) | 1984-04-09 | 1989-02-17 | Sandoz Sa | IMPROVEMENTS ON INTERLEUKIN THERAPY |
EP0169146A3 (en) | 1984-07-20 | 1988-07-20 | Merck & Co. Inc. | Monoclonal antibodies directed against the cellular receptor of human rhinovirus |
US4698420A (en) * | 1985-02-25 | 1987-10-06 | Xoma Corporation | Antibody hybrid molecules and process for their preparation |
US5077195A (en) * | 1985-03-01 | 1991-12-31 | Board Of Reagents, The University Of Texas System | Polypeptides complementary to peptides or proteins having an amino acid sequence or nucleotide coding sequence at least partially known and methods of design therefor |
US4975282A (en) | 1985-06-26 | 1990-12-04 | The Liposome Company, Inc. | Multilamellar liposomes having improved trapping efficiencies |
EP0225130B1 (en) | 1985-11-22 | 1991-10-30 | Takeda Chemical Industries, Ltd. | Liposome composition |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
WO1988001649A1 (en) | 1986-09-02 | 1988-03-10 | Genex Corporation | Single polypeptide chain binding molecules |
US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5869620A (en) * | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
US5260203A (en) * | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
JP2666345B2 (en) | 1987-04-16 | 1997-10-22 | 武田薬品工業株式会社 | Liposome preparation and method for producing the same |
US5284931A (en) * | 1987-05-04 | 1994-02-08 | Dana Farber Cancer Institute | Intercellular adhesion molecules, and their binding ligands |
US5565550A (en) * | 1987-05-04 | 1996-10-15 | Dana Farber Cancer Institute | Antibodies to ICAM-2, and fragments thereof |
DE3854536T2 (en) | 1987-05-04 | 1996-03-07 | Dana Farber Cancer Inst Inc | Intercellular adhesion molecules and their binding ligands. |
US5273876A (en) | 1987-06-26 | 1993-12-28 | Syntro Corporation | Recombinant human cytomegalovirus containing foreign gene |
US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
AU643189B2 (en) | 1988-09-06 | 1993-11-11 | Xoma Corporation | Production of chimeric mouse-human antibodies with specificity to human tumor antigens |
EP0365837B1 (en) | 1988-09-28 | 1995-08-02 | Dana Farber Cancer Institute | Intercellular adhesion molecules, and their binding ligands |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
CA2045129A1 (en) | 1989-02-01 | 1990-08-02 | Alfred I. Geller | Herpes simplex virus type i expression vector |
US5665577A (en) | 1989-02-06 | 1997-09-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
ATE79270T1 (en) | 1989-03-09 | 1992-08-15 | Boehringer Ingelheim Pharma | USE OF INTERCELLULAR ADHAESION MOLECULES AND THEIR BINDING LIGANDS IN THE TREATMENT OF ASTHMA. |
US5081584A (en) * | 1989-03-13 | 1992-01-14 | United States Of America | Computer-assisted design of anti-peptides based on the amino acid sequence of a target peptide |
AU627591B2 (en) | 1989-06-19 | 1992-08-27 | Xoma Corporation | Chimeric mouse-human km10 antibody with specificity to a human tumor cell antigen |
US5324510A (en) * | 1989-09-01 | 1994-06-28 | Boehringer Ingelheim Pharmaceuticals, Inc. | Use of antibodies to intercellular adhesion molecule-1 (ICAM-1) in the treatment of asthma |
EP0453554A4 (en) | 1989-11-13 | 1993-02-17 | Xoma Corporation | Chimeric mouse human antibodies with specificity to hiv antigens |
WO1991007418A1 (en) | 1989-11-13 | 1991-05-30 | Xoma Corporation | Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen |
CA2044627A1 (en) | 1989-11-13 | 1991-05-14 | Randy R. Robinson | Chimeric mouse human antibodies with specificity to hiv antigens |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
GB9009548D0 (en) | 1990-04-27 | 1990-06-20 | Celltech Ltd | Chimeric antibody and method |
EP0459577A3 (en) * | 1990-06-01 | 1992-08-05 | Merck & Co. Inc. | Microbially expressed portions of a monoclonal antibody block rhinovirus attachment to cell receptors |
US5723286A (en) * | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
WO1992005266A2 (en) | 1990-09-21 | 1992-04-02 | Viagene, Inc. | Packaging cells |
US5582996A (en) * | 1990-12-04 | 1996-12-10 | The Wistar Institute Of Anatomy & Biology | Bifunctional antibodies and method of preparing same |
EP0572401B2 (en) | 1991-02-19 | 2007-11-07 | The Regents of the University of California | Viral particles having altered host range |
GB9105383D0 (en) | 1991-03-14 | 1991-05-01 | Immunology Ltd | An immunotherapeutic for cervical cancer |
US5223396A (en) * | 1991-05-03 | 1993-06-29 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for detecting organ transplant rejection |
DE69233254T2 (en) | 1991-06-14 | 2004-09-16 | Genentech, Inc., South San Francisco | Humanized Heregulin antibody |
WO1993006213A1 (en) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5565332A (en) * | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5716805A (en) * | 1991-10-25 | 1998-02-10 | Immunex Corporation | Methods of preparing soluble, oligomeric proteins |
US6025165A (en) * | 1991-11-25 | 2000-02-15 | Enzon, Inc. | Methods for producing multivalent antigen-binding proteins |
JPH07501451A (en) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | Multivalent antigen binding protein |
US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
DE69233204T2 (en) * | 1991-12-13 | 2004-07-15 | Xoma Corp., Berkeley | METHOD AND MATERIALS FOR THE PRODUCTION OF MODIFIED VARIABLE ANTIBODY DOMAINS AND THEIR THERAPEUTIC USE |
ES2102007T3 (en) | 1992-01-23 | 1997-07-16 | Merck Patent Gmbh | MONOMER AND DIMER ANTIBODY FRAGMENT FUSION PROTEINS. |
US6129914A (en) * | 1992-03-27 | 2000-10-10 | Protein Design Labs, Inc. | Bispecific antibody effective to treat B-cell lymphoma and cell line |
AU3972893A (en) | 1992-04-03 | 1993-11-08 | Baylor College Of Medicine | Gene therapy using the intestine |
US6329507B1 (en) * | 1992-08-21 | 2001-12-11 | The Dow Chemical Company | Dimer and multimer forms of single chain polypeptides |
US5639641A (en) * | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US5832448A (en) * | 1996-10-16 | 1998-11-03 | Health Hero Network | Multiple patient monitoring system for proactive health management |
WO1994012520A1 (en) * | 1992-11-20 | 1994-06-09 | Enzon, Inc. | Linker for linked fusion polypeptides |
WO1994012629A1 (en) | 1992-12-02 | 1994-06-09 | Baylor College Of Medicine | Episomal vectors for gene therapy |
ATE199392T1 (en) | 1992-12-04 | 2001-03-15 | Medical Res Council | MULTIVALENT AND MULTI-SPECIFIC BINDING PROTEINS, THEIR PRODUCTION AND USE |
US6307026B1 (en) * | 1992-12-10 | 2001-10-23 | Celltech Limited | Humanized antibodies directed against A33 antigen |
FR2702160B1 (en) | 1993-03-02 | 1995-06-02 | Biovecteurs As | Synthetic particulate vectors and method of preparation. |
US5491074A (en) * | 1993-04-01 | 1996-02-13 | Affymax Technologies Nv | Association peptides |
CA2163218C (en) * | 1993-05-18 | 2002-09-10 | Mohamed Chokri | New macrophages, process for preparing the same and their use as active substances of pharmaceutical compositions |
AU7353494A (en) | 1993-11-12 | 1995-05-29 | Case Western Reserve University | Episomal expression vector for human gene therapy |
US5928944A (en) | 1994-02-04 | 1999-07-27 | The United States Of America As Represented By The Department Of Health And Human Services | Method of adenoviral-medicated cell transfection |
CA2117668C (en) | 1994-03-09 | 2005-08-09 | Izumu Saito | Recombinant adenovirus and process for producing the same |
GB9409768D0 (en) * | 1994-05-16 | 1994-07-06 | Medical Res Council | Trimerising polypeptides |
US5604090A (en) | 1994-06-06 | 1997-02-18 | Fred Hutchinson Cancer Research Center | Method for increasing transduction of cells by adeno-associated virus vectors |
US5763733A (en) * | 1994-10-13 | 1998-06-09 | Enzon, Inc. | Antigen-binding fusion proteins |
US5693508A (en) | 1994-11-08 | 1997-12-02 | Chang; Lung-Ji | Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats |
US5721340A (en) * | 1994-11-28 | 1998-02-24 | The Wistar Institute Of Anatomy & Biology | p53 proteins with altered tetramerization domains |
US5573925A (en) * | 1994-11-28 | 1996-11-12 | The Wistar Institute Of Anatomy And Biology | P53 proteins with altered tetramerization domains |
US5632448A (en) * | 1995-01-25 | 1997-05-27 | Ransburg Corporation | Rotary powder applicator |
US5731168A (en) * | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
JP3770333B2 (en) | 1995-03-15 | 2006-04-26 | 大日本住友製薬株式会社 | Recombinant DNA virus and method for producing the same |
EP0827544B1 (en) * | 1995-05-23 | 2004-08-18 | MorphoSys AG | Multimeric proteins |
US6110456A (en) | 1995-06-07 | 2000-08-29 | Yale University | Oral delivery or adeno-associated viral vectors |
JP2783276B2 (en) * | 1995-07-04 | 1998-08-06 | 日本電気株式会社 | Method for manufacturing semiconductor device |
JPH11510389A (en) | 1995-07-31 | 1999-09-14 | アメリカ合衆国 | Extending protein-protein interaction surfaces to inactivate cellular protein functions |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
EP0868521A2 (en) | 1995-12-22 | 1998-10-07 | Somatogen Inc. | Globins containing binding domains |
DK0914155T3 (en) * | 1996-03-25 | 2006-06-26 | Medarex Inc | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
US5861397A (en) | 1996-10-03 | 1999-01-19 | Vical Incorporated | Piperazine based cytofectins |
US6096291A (en) | 1996-12-27 | 2000-08-01 | Biovector Therapeutics, S.A. | Mucosal administration of substances to mammals |
IL132239A0 (en) * | 1997-04-07 | 2001-03-19 | Genentech Inc | Humanized antibodies and methods for forming humanized antibodies |
DK1039931T3 (en) | 1997-12-01 | 2005-08-08 | Fang Fang | Multivalent recombinant antibodies to treat HRV infections |
JPH11228446A (en) * | 1998-02-16 | 1999-08-24 | Mitsubishi Chemical Corp | Antimalarial agent |
US20020165153A1 (en) | 1998-04-06 | 2002-11-07 | Peter Angel | Transcription factors and their use |
US5965712A (en) * | 1998-06-19 | 1999-10-12 | Virginia Commonwealth University | LZ-CD23 chimera for inhibition of IgE-mediated allergic disease |
PT1121382E (en) * | 1998-10-16 | 2006-10-31 | Biogen Idec Inc | BETA INTERFERENCE FUSE PROTEINS AND THEIR RESPECTIVE USES |
US20030035798A1 (en) * | 2000-08-16 | 2003-02-20 | Fang Fang | Humanized antibodies |
DE69942671D1 (en) * | 1998-12-01 | 2010-09-23 | Facet Biotech Corp | HUMANIZED ANTIKOERPER AGAINST GAMMA INTERFERON |
WO2001000814A2 (en) | 1999-06-25 | 2001-01-04 | Universität Zürich | Hetero-associating coiled-coil peptides and screenign method therefor |
WO2001019842A1 (en) | 1999-09-17 | 2001-03-22 | Genzyme Transgenics Corporation | Subunit optimized fusion proteins |
AUPQ425699A0 (en) * | 1999-11-25 | 1999-12-23 | University Of Newcastle Research Associates Limited, The | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
CA2382165A1 (en) * | 1999-12-08 | 2001-06-14 | Genset S.A. | Full-length human cdnas encoding potentially secreted proteins |
EP1290027B1 (en) | 2000-04-28 | 2009-09-09 | Planet Biotechnology, Inc. | Immunoadhesin for the prevention of rhinovirus infection |
JP2005522192A (en) * | 2001-07-19 | 2005-07-28 | パーラン セラピューティクス, インコーポレイテッド | Multimeric proteins and methods of making and using multimeric proteins |
JP4236000B2 (en) | 2003-09-25 | 2009-03-11 | 元気株式会社 | 3D image processing apparatus, 3D image processing method and program |
-
2001
- 2001-07-19 US US09/910,483 patent/US20030035798A1/en not_active Abandoned
-
2002
- 2002-07-19 DK DK02798403.8T patent/DK1414861T3/en active
- 2002-07-19 AT AT02798403T patent/ATE490276T1/en not_active IP Right Cessation
- 2002-07-19 EP EP02798403A patent/EP1414861B1/en not_active Expired - Lifetime
- 2002-07-19 CA CA2454361A patent/CA2454361C/en not_active Expired - Fee Related
- 2002-07-19 AU AU2002363027A patent/AU2002363027C1/en not_active Ceased
- 2002-07-19 DE DE60238485T patent/DE60238485D1/en not_active Expired - Lifetime
- 2002-07-19 ES ES02798403T patent/ES2356896T3/en not_active Expired - Lifetime
- 2002-07-19 WO PCT/US2002/023002 patent/WO2003035696A2/en active Application Filing
- 2002-07-19 CA CA2793019A patent/CA2793019A1/en not_active Abandoned
- 2002-07-19 EP EP10010857A patent/EP2336186A1/en not_active Withdrawn
- 2002-07-19 JP JP2003538209A patent/JP4516312B2/en not_active Expired - Fee Related
-
2006
- 2006-09-11 US US11/519,322 patent/US7696324B2/en not_active Expired - Fee Related
-
2008
- 2008-12-18 AU AU2008258214A patent/AU2008258214B2/en not_active Ceased
-
2009
- 2009-05-15 JP JP2009119326A patent/JP2009183303A/en active Pending
-
2010
- 2010-03-26 US US12/748,304 patent/US8586712B2/en not_active Expired - Fee Related
-
2012
- 2012-06-07 AU AU2012203365A patent/AU2012203365A1/en not_active Abandoned
-
2013
- 2013-02-14 JP JP2013026399A patent/JP2013116119A/en active Pending
- 2013-11-18 US US14/083,146 patent/US20140308269A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991016927A1 (en) * | 1990-04-27 | 1991-11-14 | Celltech Limited | Humanized cdr-grafted anti-icam-1 antibodies, methods of preparation and usage thereof |
Non-Patent Citations (3)
Title |
---|
CHARLES CATHERINE H ET AL: "Prevention of human rhinovirus infection by multivalent Fab molecules directed against ICAM-1.", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 47, no. 5, 20 May 2003 (2003-05-20), pages 1503 - 1508, XP009015720, ISSN: 0066-4804 * |
FOOTE J ET AL: "ANTIBODY FRAMEWORK RESIDUES AFFECTING THE CONFORMATION OF THE HYPERVARIABLE LOOPS", JOURNAL OF MOLECULAR BIOLOGY, vol. 224, no. 2, 1992, pages 487 - 499, XP000564649, ISSN: 0022-2836 * |
LUO GUANG X ET AL: "Humanization of an anti-ICAM-1 antibody with over 50-fold affinity and functional improvement.", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 275, no. 1-2, 2003, pages 31 - 40, XP004416747, ISSN: 0022-1759 * |
Also Published As
Publication number | Publication date |
---|---|
US20030035798A1 (en) | 2003-02-20 |
ES2356896T3 (en) | 2011-04-14 |
WO2003035696A2 (en) | 2003-05-01 |
ATE490276T1 (en) | 2010-12-15 |
AU2002363027C1 (en) | 2009-04-30 |
JP4516312B2 (en) | 2010-08-04 |
DE60238485D1 (en) | 2011-01-13 |
JP2009183303A (en) | 2009-08-20 |
US20070071742A1 (en) | 2007-03-29 |
AU2008258214A1 (en) | 2009-01-15 |
AU2002363027B2 (en) | 2008-09-18 |
CA2454361A1 (en) | 2003-05-01 |
CA2793019A1 (en) | 2003-05-01 |
EP2336186A1 (en) | 2011-06-22 |
CA2454361C (en) | 2013-01-08 |
US8586712B2 (en) | 2013-11-19 |
US20110044976A1 (en) | 2011-02-24 |
EP1414861A2 (en) | 2004-05-06 |
EP1414861B1 (en) | 2010-12-01 |
DK1414861T3 (en) | 2011-03-21 |
JP2005524385A (en) | 2005-08-18 |
JP2013116119A (en) | 2013-06-13 |
US20140308269A1 (en) | 2014-10-16 |
AU2012203365A1 (en) | 2012-06-28 |
US7696324B2 (en) | 2010-04-13 |
AU2008258214B2 (en) | 2012-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003035696A3 (en) | Humanized antibodies against icam-1, their production and uses | |
WO2002072635A3 (en) | Specific binding members | |
WO2004064595A3 (en) | Multivalent constructs for therapeutic and diagnostic applications | |
EP2620450A3 (en) | Anti-CTLA-4 antibody compositions | |
WO2004027822A3 (en) | Oriented nanostructures and methods of preparing | |
WO2005097832A3 (en) | Humanized anti-tgf-beta antibodies | |
WO2003100008A3 (en) | Neutralizing human anti-igfr antibody | |
EP2210612A3 (en) | Macrocyclic antagonists of the motilin receptor | |
WO2002072736A3 (en) | Demulsification of water-in-oil emulsions | |
EP2135879A3 (en) | Ligand | |
AU2002349477A1 (en) | Bicyclic derivative, process for producing the same, and use | |
WO2005099756A3 (en) | ErbB ANTAGONISTS FOR PAIN THERAPY | |
EP2502935A3 (en) | Improved antibodies having altered effector function and methods for making the same | |
WO2007133290A3 (en) | Anti-ox40l antibodies and methods using same | |
WO2001014424A3 (en) | Human ctla-4 antibodies and their uses | |
WO2008060705A3 (en) | Anti-dll4 antibodies and methods using same | |
WO2002072865A3 (en) | Methods, kits and compositions of combination oligomers | |
WO2003048301A3 (en) | Anti-hla-dr antibodies and the methods of using thereof | |
WO2004058822A3 (en) | Generation of immunoglobulin molecules with predetermined specificity | |
WO2004087735A3 (en) | Proteolytic and covalent antibodies | |
WO2005034865A3 (en) | Water-soluble chitosan having low endotoxin concentration and methods for making and using the same | |
ZA200402138B (en) | Catalyst and it use for improving the pour point of hydrocarbon charges. | |
EP1584701A4 (en) | Steel product for induction hardening, induction-hardened member using the same, and methods for producing them | |
ZA200309943B (en) | Process for the production of liquid hydrocarbons. | |
WO2003043648A3 (en) | Sfcyr iib or sfcyr iii for the treatment of auto-immune diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003538209 Country of ref document: JP Ref document number: 2454361 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002363027 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002798403 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002798403 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |